SEC Form 4 · accession 0002089511-26-000002
MapLight Therapeutics, Inc. · MPLT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nanna Liebach Luneborg
Director
Period of report
Jun 23, 2026
Accepted (ET)
Jun 25, 2026 · 5:57 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001770069
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Voting Common StockF1,F2 | Jun 23, 2026 | A | 3,932 | $0.00 | A | 3,932 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $28.64 | Jun 23, 2026 | A | 14,902 | A | — | Jun 22, 2036 | Voting Common Stock | 14,902 | 14,902 | D |
Explanation of responses
- F1Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.
- F2Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
- F3Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.